NASDAQ:HBIO Harvard Bioscience (HBIO) Stock Price, News & Analysis $6.35 +0.20 (+3.25%) Closing price 04:00 PM EasternExtended Trading$6.22 -0.13 (-2.09%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Harvard Bioscience Stock (NASDAQ:HBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Harvard Bioscience alerts:Sign Up Key Stats Today's Range$6.07▼$6.4050-Day Range$5.00▼$7.2452-Week Range$3.75▼$9.40Volume16,624 shsAverage Volume43,583 shsMarket Capitalization$28.64 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingHold Company Overview Harvard Bioscience, Inc. develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics. Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools. The company serves its customers via direct sales and an extensive distributor network, with significant operations in North America, Europe and the Asia‐Pacific region. Founded in 1901 and headquartered in Holliston, Massachusetts, Harvard Bioscience has grown through organic innovation and strategic acquisitions to support the evolving needs of life science research. The company maintains manufacturing and R&D facilities in the United States and Europe and is managed by an experienced team of professionals with backgrounds in engineering, sales and scientific product development.AI Generated. May Contain Errors. Read More Harvard Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks17th Percentile Overall ScoreHBIO MarketRank™: Harvard Bioscience scored higher than 17% of companies evaluated by MarketBeat, and ranked 559th out of 627 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingHold Consensus RatingHarvard Bioscience has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Downside RiskHarvard Bioscience has a consensus price target of $6.00, representing about 5.5% downside from its current price of $6.35.Amount of Analyst CoverageHarvard Bioscience has only been the subject of 1 research reports in the past 90 days.Read more about Harvard Bioscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Harvard Bioscience is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harvard Bioscience is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarvard Bioscience has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Harvard Bioscience's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.48% of the float of Harvard Bioscience has been sold short.Short Interest Ratio / Days to CoverHarvard Bioscience has a short interest ratio ("days to cover") of 3.43, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Harvard Bioscience has recently decreased by 15.96%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHarvard Bioscience does not currently pay a dividend.Dividend GrowthHarvard Bioscience does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Harvard Bioscience this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for HBIO on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Harvard Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders20.30% of the stock of Harvard Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.87% of the stock of Harvard Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harvard Bioscience's insider trading history. Receive HBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HBIO Stock News HeadlinesHarvard Bioscience (NASDAQ:HBIO) Stock Price Passes Above 200 Day Moving Average - Here's WhyJuly 2, 2026 | americanbankingnews.comHarvard Bioscience Shareholders Expand Equity Plans, Elect DirectorsJune 2, 2026 | tipranks.comSell Tesla, Buy the New King of FSD CarsIn 2023, Marc Chaikin's system flagged an automotive stock as bearish - and it fell 35% shortly after. Today, that same stock has earned a 'Very Bullish' rating after forming a major partnership with Nvidia to power AI-driven autonomous vehicles. This barely-known company was selected to handle the complex job of getting Nvidia's self-driving AI safely inside vehicles - positioning it at the center of a massive trend most investors are still missing through Tesla.July 6 at 1:00 AM | Chaikin Analytics (Ad)Harvard Bioscience Balances Margin Gains With Soft SalesMay 19, 2026 | tipranks.comHBIO Q1 2026 Earnings TranscriptMay 14, 2026 | finance.yahoo.comHarvard Bioscience: Q1 Earnings SnapshotMay 14, 2026 | finance.yahoo.comHarvard Bioscience, Inc.: Harvard Bioscience Announces First Quarter 2026 Financial ResultsMay 12, 2026 | finanznachrichten.deHarvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comSee More Headlines HBIO Stock Analysis - Frequently Asked Questions How have HBIO shares performed this year? Harvard Bioscience's stock was trading at $6.6880 at the beginning of the year. Since then, HBIO stock has decreased by 5.1% and is now trading at $6.35. How were Harvard Bioscience's earnings last quarter? Harvard Bioscience, Inc. (NASDAQ:HBIO) issued its earnings results on Tuesday, May, 12th. The medical instruments supplier reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.29. The medical instruments supplier had revenue of $20.76 million for the quarter, compared to analysts' expectations of $21.20 million. Harvard Bioscience had a negative trailing twelve-month return on equity of 25.78% and a negative net margin of 11.44%. Read the conference call transcript. When did Harvard Bioscience's stock split? Shares of Harvard Bioscience reverse split before market open on Monday, March 16th 2026.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, March 15th 2026. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Does Harvard Bioscience have any subsidiaries? Harvard Bioscience subsidiaries include these companies: Data Sciences International. How do I buy shares of Harvard Bioscience? Shares of HBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Harvard Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harvard Bioscience investors own include YETI (YETI), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Alphabet (GOOG), Stag Industrial (STAG) and Tesla (TSLA). Company Calendar Last Earnings5/12/2026Today7/06/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 HBIO's financial health is in the Green zone, according to TradeSmith. HBIO has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorComputer and Technology Industry INSTRU - SCIENTFC Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:HBIO CIK1123494 Webwww.harvardbioscience.com Phone(508) 893-8999Fax508-429-5732Employees490Year Founded1901Price Target and Rating Average Price Target for Harvard Bioscience$6.00 High Price Target$6.00 Low Price Target$6.00 Potential Upside/Downside-5.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$56.70 million Net Margins-11.44% Pretax Margin-11.57% Return on Equity-25.78% Return on Assets-4.37% Debt Debt-to-Equity Ratio3.60 Current Ratio1.99 Quick Ratio1.06 Sales & Book Value Annual Sales$86.55 million Price / Sales0.33 Cash Flow$11.98 per share Price / Cash Flow0.53 Book Value$3.07 per share Price / Book2.07Miscellaneous Outstanding Shares4,510,000Free Float3,594,000Market Cap$28.64 million OptionableOptionable Beta1.49 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:HBIO) was last updated on 7/6/2026 by MarketBeat.com Staff. From Our PartnersAmazon, Google, Meta, and Microsoft just committed $700 billionAmazon, Google, Meta, and Microsoft have committed $700 billion this year alone to AI infrastructure - more th...True Market Insiders | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]The government just committed $200 billion to building computer chips on American soil - one of the largest te...Eagle Publishing | SponsoredAre you leaving Social Security money on the table?Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....Money Pickle | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredThe Warsh Fed and what it could mean for your savingsThe Fed just changed hands, and Reagan Gold Group says there may be a short window before the impact shows up ...Reagan Gold Group | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harvard Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harvard Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
